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Previewsdeacetylase, Sirt3 (Brown et al., 2014). All
of this is wonderful news for the future of
NR and NAD-boosting neurotherapeutic
approaches. Because Sirt3 was required
for NR function, it stands to reason that
NR increased mitochondrial NAD synthe-
sis. However, these results do not rule out
WldS functions in the axonal cytosol nor
exclude a role for axonal NMN as a
degenerative signal.
The way to synthesize the concepts of
NMN as neurotoxic and NAD as neuro-
protective is to appreciate that cytosolic
NAD is required to generate ATP for
anterograde vesicular transport. Indeed,
increasing evidence indicates that glyco-
lytic enzymes and Nmnat2 are vesicle-
associated, which allows such organelles
to traverse the length of neurons with
‘‘on-board’’ ATP production (Zala et al.,
2013). Because Nmnat2 is unstable,
depletion of the ability to convert NMN to
NAD could limit glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) and dam-
age neuronal energetics because the pre-
paratory phase of glycolysis (upstream of
GAPDH) costs two ATP per input glucose.
Without an ATP payoff and the resulting
production of cytosolic GTP, the ability to
translate and transport new Nmnat2 and
other proteins would be greatly compro-mised, and NMN accumulation could be
readbysuchdamagedneuronsasasignal
to die back. In thepresenceofWldSorNR,
I predict that cytosolic and mitochondrial
NAD formation are improved, with axonal
NAD preserving transport of GAPDH,
Nmnat2, and other molecules along
lengthy microtubules. So long as antero-
grade transport is functioning, there
should not be accumulation of NMN or a
degenerative signal produced by NMN.
The most recent result (Brown et al.,
2014) also demands a role for mitochon-
drial NAD, which is thought to be pro-
duced from mitochondrial transport of
cytosolic NMN. Why Sirt3 would need
to deacetylate mitochondrial proteins
to prevent neurodegeneration is not
known, though mitochondrial proteins
are frequently inactivated by acetylation.
Future experiments are expected to clarify
whether loud noise inducesPARP in away
that makes GAPDH require increased
axonal synthesis of NAD, whether noise
alters mitochondrial metabolism in a
manner that drives acetyl modifications
onto protein targets, to what degree ROS
damage is attenuated by provision of
NR, and whether NR can be used to pre-
vent or treat additional neurodegenerative
diseases and conditions.Cell Metabolism 20,REFERENCES
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Myriad strategies have been explored to compensate for the lack of dystrophin or to skip mutations that
cause the lethal disease Duchenne muscular dystrophy (DMD). A new study shows that gene editing strate-
gies used by bacteria can be applied in zygotes of a mouse model of DMD to correct the genetic defect that
causes muscular dystrophy (Long et al., 2014).Duchenne muscular dystrophy (DMD) is
a lethal, X-linked recessive disease
affecting approximately 1 of 3,500 bornmales. Upon discovery that DMD is a
monogenic disease caused by mutations
of the dystrophin gene, hopes were highthat targeting thewild-typegene todystro-
phicmuscle would provide a cure. In inter-
vening decades, an impressive array ofDecember 2, 2014 ª2014 Elsevier Inc. 927
Figure 1. Gene Editing Mediated by CRISPR/Cas9 in mdx Zygotes
Schematic representation of the strategy used to induce correction of the dystrophin gene defect in the
germline of dystrophin-deficient mice. hCas9 RNA and single guide RNA (sgRNA) were coinjected with
an ssODN template designed to target and correct the genetic defect in mouse zygotes. Injected zygotes
were then transferred into the oviducts of pseudopregnant ICR female mice. Themajority of the littermates
that experienced editing of the dystrophin gene contained indels generated by NHEJ. Correction medi-
ated by HDR occurred in approximately 5% of all newborn mdx mice.
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Previewsstrategies has been explored for the treat-
ment of the disease. Among those, tech-
niques for editing of the dystrophin gene
in vivo are most appealing because they
may permanently correct the defect. How-
ever, only limited, local gene correction
has been achieved by intramuscular
injection of RNA/DNA oligonucleotides
or single-stranded oligodeoxynucleotides
(ssODNs) inanimalmodelsofDMD(Rando
et al., 2000; Kayali et al., 2010), leaving the
field of experimental therapeutics in
search of mechanisms for systemic and
persistent correction of endogenous mu-
tations that causeDMD.Now,a teamof in-
vestigators has ridden the crest of the
wave of recent discoveries that demon-
strate that bacterial gene editing mecha-
nisms using Cas9 endonuclease can be
used to modify the structure of vertebrate
genes, this time to cure muscular dystro-
phy (Long et al., 2014) (Figure 1).
Many bacteria excise viral DNA from
invasive viruses, which is then inter-
spersed within the bacterial DNA at
a clustered, regularly interspaced, short
palindromic repeats (CRISPR) locus,
from which RNAs can be later transcribed
to guide an endonuclease to viral DNA
during subsequent infections. Cas9 then
cleaves double-stranded DNAs if
directed to the sequence by a guide
RNA containing the sequence, providing
the bacterium with a form of innate immu-
nity. Double-strand breaks can then be928 Cell Metabolism 20, December 2, 2014 ªrepaired by two mechanisms. In one, the
break is repaired by nonhomologous
end joining (NHEJ), which can lead to
insertion/deletion mutations (indel). Alter-
natively, homology directed repair (HDR)
occurs if an exogenous template is pro-
vided so that engineered sequences can
be inserted at the targeted site. By inject-
ing Cas9 with the appropriate guide RNA
and HDR template into mdx zygotes at
the one-cell stage (Figure 1), Long et al.
(2014) were able to correct the mdx point
mutation in some zygotes, producing
mice that were free of pathology. In
particular, mdx mice that experienced
more than 40% gene correction at the
target site by NHEJ or HDR displayed
normal dystrophin expression at the cell
membrane. Mice with those relatively
high levels of gene repair also showed
normalization of muscle histology, recov-
ery of muscle strength, and an absence of
pathological leakiness of the muscle cell
membrane, which is a characteristic of
dystrophin deficiency. Because the guide
RNA may cause undesirable, unintended
mutations, the investigators also tested
for off-target mutations in the treated
mdx mice. However, none of the 32
most likely off-target sites showed an in-
crease in indel mutations (Long et al.,
2014). The findings show unequivocally
that the CRISPR/Cas9 system can be ex-
ploited to permanently repair the genetic
defect that causes mdx dystrophy.2014 Elsevier Inc.Two therapeutic strategies are avail-
able to attempt to use CRISPR/Cas9
technology to treat DMD. The first would
apply the tools to human, one-cell zy-
gotes, as used in mdx mice. However,
the specific dystrophin mutation of the
maternal carriers of the disease would
have to be known so that guide RNA
could be designed to target the nuclease
to the mutation site. Unfortunately, about
one-third of dystrophin mutations are
spontaneous mutations that cannot be
addressed by this strategy (Davie and
Emery, 1978). In addition, large deletion
mutations could exceed the size of func-
tional templates; the mdx mutation that
was repaired by the CRISPR system is a
point mutation that could be corrected
by HDR or NHEJ, but point mutations
comprise only about 15% of DMD muta-
tions. Mosaicism also presents a chal-
lenge. Individual pups generated from
treated mdx zygotes varied from 2% to
100% in the proportion of dystrophin
genes that were repaired by treatment.
Low levels of mosaicism are attributable
to insufficient time between RNA injection
into the zygote and the first cell division
to permit translation of enough Cas9 to
mediate biallelic mutagenesis (Yen et al.,
2014). In mice, the first division occurs in
about 24 hr. In human zygotes in vitro,
only about 18% of the zygotes reach the
first division in 24 hr (Shoukir et al.,
1997), so mosaicism may be a larger
problem with DMD treatments.
Despite the challenges for developing
the CRISPR/Cas9 strategies for correct-
ing DMD mutations in zygotes, the
approach offers unique advantages. First,
by correcting the mutation in the zygote,
the embryo will develop tolerance for dys-
trophin during normal development of the
immune system, thereby avoiding the
possibility that the newly restored dystro-
phin protein would be seen as foreign and
initiate a cellular immune response. More
importantly, the treatments at the one-
cell zygote stage can lead to a correction
of the defect in the germline. That correc-
tion can cure the disease not only in the
males who would otherwise be born with
DMD, but also correct the mutation in fe-
males who would otherwise be carriers
transmitting the mutation to their future
progeny. In fact, recent findings show
that gene correction using CRISPR tech-
nology will persist in the progeny of
treated animals. Gene correction of the
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Previewsmutation in the Crygc gene responsible
for causing cataracts was achieved by
the CRISPR/Cas9 system in mouse zy-
gotes and persisted in the progeny of
treated mice (Wu et al., 2013).
The second strategy would be to use
CRISPR/Cas9 technology to treat DMD
postnatally. This approach has the advan-
tage of applicability to all DMD patients,
regardless ofwhether themutationwas in-
herited or spontaneous. However, the
challenges of mosaicism, off-target ef-
fects, and immunogenicity would remain.
In addition, an efficient mechanism to
deliver the Cas9/guide RNA/template to
patients requires development, and this
is an almost completely unexplored
issue in adult mammals. Recent findings
showed that successful gene editing with
Cas9 could be achieved in hepatocytes
after intravascular injections of Cas9/
guide RNA/template into mice carrying a
mutation for fumarylacetoacetate hydro-
lase, which causes a fatal liver disease
(Yin et al., 2014). That finding suggeststhat postnatal genome editing for DMD
may also hold promise for functional re-
covery. Although muscle fibers are post-
mitotic and lack proteins required for
homologous recombination andare there-
fore refractory to HDR-mediated correc-
tion (Hsu et al., 2014), a population ofmus-
cle stem cells (satellite cells) that reside in
mature skeletal muscle are viable targets
for Cas9-mediated gene editing.
The exciting findings and clever exper-
imental design of Dr. Olson and his col-
leagues have illuminated a path for
correction of dystrophin mutations not
only in somatic cells to alleviate the dis-
ease in individuals, but also for correction
in the germline, which could feasibly elim-
inate the disease in the progeny, though
the road to clinical application may be
long.REFERENCES
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Central MC4R pathways are well established as integrators of peripheral signals in the control of energy
balance. In this issue, Panaro et al. (2014) identify thatMC4Rs expressed on intestinal enteroendocrine L cells
regulate PYY and GLP-1 secretion, two gut hormones implicated in the regulation of energy and glucose
homeostasis.Feeding bouts are regulated by complex,
integrated neural and endocrine networks
in a process that attempts to optimize use
of nutrient availability in the context of
changing energy requirements. Hormonal
signals of ‘‘long-term’’ energy storage,
such as the adipokine leptin, act centrally
to modulate food intake (Morton et al.,2014). Feeding behavior is also modu-
lated centrally by an array of gut-derived
hormones that either promote initiation
(orexigenic) or termination (anorexigenic)
of feeding, thus serving as ‘‘short-term’’
signals of energy availability and regula-
tors of meal size (Morton et al., 2014).
For example, secretion of the orexigenichormone ghrelin from gastric mucosal
endocrine cells progressively increases
in the absence of nutrients. In contrast,
enteroendocrine L cells release the
anorexigenic hormones peptide YY (PYY)
and glucagon-like peptide-1 (GLP-1) in
response to nutrient stimulation. These
‘‘short- and long-term’’ energy signalsDecember 2, 2014 ª2014 Elsevier Inc. 929
